Anticancer potential of mebendazole against chronic myeloid leukemia: in silico and in vitro studies revealed new insights about the mechanism of action

• Autori principali: Julio Paulino Daniel (Autore), Felipe Pantoja Mesquita (Autore), Emerson Lucena Da Silva (Autore), Pedro Filho Noronha de Souza (Autore), Luina Benevides Lima (Autore), Lais Lacerda Brasil de Oliveira (Autore), Maria Elisabete Amaral de Moraes (Autore), Caroline de Fátima Aquino Moreira-Nunes (Autore), Rommel Mario Rodríguez Burbano (Autore), Geancarlo Zanatta (Autore), Raquel Carvalho Montenegro (Autore)
• Natura: Libro
• Pubblicazione: Frontiers Media S.A., 2022-08-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Chronic myeloid leukemia (CML) is caused by constitutively active fusion protein BCR-ABL1, and targeting ABL1 is a promising therapy option. Imatinib, dasatinib, and nilotinib have all been shown to work effectively in clinical trials. ABL1 mutations, particularly the T315I gate-keeper mutation, cau...